NF Nomura Shareholder Yield 70 Fund (2529)

Overview

Lucid Diagnostics Inc. stands as a pivotal entity within the United States, focusing its expertise on the realm of commercial-stage medical diagnostics technology. Spearheaded towards addressing the needs of patients afflicted with gastroesophageal reflux disease (GERD), Lucid Diagnostics zeroes in on the demographic at heightened risk of esophageal precancer and the notably aggressive esophageal adenocarcinoma. Established in the year 2018 and nestled in the bustling heart of New York, New York, Lucid Diagnostics proudly operates under the aegis of its parent company, PAVmed Inc. Through its innovative approach and dedicated efforts, it seeks to etch a significant mark in the prevention of esophageal cancer fatalities by enabling early detection of precancerous conditions in GERD patients at risk.

Products and Services

• EsoGuard Esophageal DNA Test

As the flagship product of Lucid Diagnostics Inc., the EsoGuard Esophageal DNA Test represents a monumental leap in the early detection of esophageal precancer. This state-of-the-art diagnostic tool is specifically designed for the identification of esophageal cell DNA alterations that may signal the onset of precancerous conditions, namely those leading to esophageal adenocarcinoma. The primary advantage of EsoGuard lies in its non-invasive testing methodology, which can be performed on samples procured via the EsoCheck Esophageal Cell Collection Device. This pioneering approach heralds a new era in the proactive management of esophageal cancer risk amongst individuals battling gastroesophageal reflux disease.

• EsoCheck Esophageal Cell Collection Device

Working in tandem with the EsoGuard test is the EsoCheck Esophageal Cell Collection Device, a crucial component in Lucid Diagnostics’ arsenal against esophageal precancer. This innovatively designed tool facilitates the safe and efficient gathering of esophageal cell samples from patients. The EsoCheck’s non-invasive nature not only enhances patient comfort but also significantly reduces the barriers to screening for esophageal adenocarcinoma precursors. By simplifying the collection process, the EsoCheck Device paves the way for a broader adoption of early diagnostic screenings, playing a pivotal role in the early detection and potential prevention of esophageal cancer.